D. Boral Capital initiated coverage of Avita Medical (RCEL) with a Buy rating and $25 price target Avita’s Recell technology has shown “promising results” in clinical trials for a variety of soft tissue and skin-related indications and Avita is “poised for significant growth” from expanding market penetration into trauma wounds, surgical wounds, and “slowly but surely chronic wounds” as awareness of the technology increases and adoption grows in hospitals and burn centers worldwide, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCEL:
- Closing Bell Movers: International Seaways up 8% on S&P600 inclusion
- Avita Medical discloses FDA premarket approval for ECELL GO mini
- Avita Medical announces FDA 510 clearance for Cohealyx
- Avita Medical enters exclusive distribution agreement with Revolution Surgical
- Avita Medical price target raised to $12 from $9 at Piper Sandler